Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is an open label pilot clinical trial on a cohort of 15 Lupus patients from the Center
for Rheumatic Disease. Clinical evaluations and laboratory tests will be done and then if
eligible, the patients will receive oral atorvastatin, at a fixed dose of 40mg/day. Statins
have been shown to induce clinical improvement in rheumatoid arthritis patients, as well as
lupus patients. The effectiveness has been noted within 8 to 14 days, we will do our study
for 3 months. Clinical and laboratory tests will be checked at the 1 and 3 month interval. We
hypothesize that statin drugs (atorvastatin) slow the progression of SLE(Systemic Lupus
Erythematosus) disease activity and down regulates TLR(Toll-like receptors) 2,4,and 9
pathways in addition to lowering lipid levels.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Center for Rheumatic Disease, Allergy, & Immunology